Company Information: Takeda Pharmaceutical Company Limited<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4502","DATE":"2025-12-19","longName":"Takeda Pharmaceutical Company Limited","company_name_ja":"\u6b66\u7530\u85ac\u54c1\u5de5\u696d(\u682a)","fullTimeEmployees":47029,"address":"","phone":"","website":"https:\/\/www.takeda.com","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":4604,"financialCurrency":"","marketCap":7272451,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":119.64,"epsForward":0,"bookValue":0,"totalRevenue":4505720000000,"OperatingIncome":464451000000,"operatingMargins":10.31,"NetIncome":-152390000000,"profitMargins":-3.3799999999999999,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-2.0499999999999998,"recommendationMean":1.8125,"recommendationKey":"buy","targetMeanPrice":6375.1875,"numberOfAnalystOpinions":15,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T05:02:11.815122\", \"ticker\": \"4502\", \"ticker_full\": \"4502.T\", \"company_name\": \"TAKEDA PHARMACEUTICAL CO LTD\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 3, \"buy\": 7, \"hold\": 5, \"sell\": 0, \"strong_sell\": 0, \"total_analysts\": 15, \"recommendation_key\": \"buy\", \"recommendation_mean\": 1.8125}, \"target_prices\": {\"has_data\": true, \"current\": 5513.0, \"high\": 7900.0, \"low\": 5600.0, \"mean\": 6375.1875, \"median\": 6401.5}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": {\"date\": \"2026-10-29\", \"eps_estimate\": 33.8, \"eps_actual\": null, \"surprise_pct\": null}, \"future_count\": 1, \"past_earnings\": [{\"date\": \"2026-07-30\", \"eps_estimate\": 53.12, \"eps_actual\": 71.65, \"surprise_pct\": 34.88}, {\"date\": \"2026-05-13\", \"eps_estimate\": -24.01, \"eps_actual\": -15.31, \"surprise_pct\": 36.25}, {\"date\": \"2026-01-28\", \"eps_estimate\": 43.14, \"eps_actual\": 65.74, \"surprise_pct\": 52.39}, {\"date\": \"2025-10-29\", \"eps_estimate\": 33.8, \"eps_actual\": -7.83, \"surprise_pct\": -123.17}, {\"date\": \"2025-07-30\", \"eps_estimate\": 49.56, \"eps_actual\": 79.4, \"surprise_pct\": 60.22}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 0.03, \"institution_pct\": 50.35, \"major_holders\": [{\"label\": \"\", \"value\": 0.03}, {\"label\": \"\", \"value\": 50.35}, {\"label\": \"\", \"value\": 50.37}, {\"label\": \"\", \"value\": 462.0}], \"institutional_holders\": [{\"holder\": \"Pacer Advisors, Inc.\", \"shares\": 2099392, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.13, \"pct_change\": 9.92, \"value\": 11573948096}, {\"holder\": \"Paradigm Asset Management Company, LLC\", \"shares\": 1600, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.0, \"pct_change\": 0.0, \"value\": 8820800}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 23123746, \"date_reported\": \"2026-04-30\", \"pct_held\": 1.44, \"pct_change\": 0.07, \"value\": 127481211698}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 15287432, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.95, \"pct_change\": 2.45, \"value\": 84279612616}, {\"holder\": \"Capital World Growth & Income Fund\", \"shares\": 13243091, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.83, \"pct_change\": -4.12, \"value\": 73009160683}, {\"holder\": \"iShares Trust-iShares Core MSCI EAFE ETF\", \"shares\": 11570680, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.72, \"pct_change\": 1.21, \"value\": 63789158840}, {\"holder\": \"Goldman Sachs TRT II-Goldman Sachs GQG Part. Intl Opportunities Fd.\", \"shares\": 10204800, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.64, \"pct_change\": 0.0, \"value\": 56259062400}, {\"holder\": \"iShares, Inc.-iShares MSCI Japan ETF\", \"shares\": 6883900, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.43, \"pct_change\": 6.22, \"value\": 37950940700}, {\"holder\": \"Fidelity Concord Street Trust-Fidelity International Index Fund\", \"shares\": 6126545, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.38, \"pct_change\": 2.35, \"value\": 33775642585}, {\"holder\": \"Capital Income Builder\", \"shares\": 5861350, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.37, \"pct_change\": 0.0, \"value\": 32313622550}, {\"holder\": \"iShares Trust-iShares MSCI EAFE ETF\", \"shares\": 5643410, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.35, \"pct_change\": 1.31, \"value\": 31112119330}, {\"holder\": \"Investment Co of America\", \"shares\": 5284612, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.33, \"pct_change\": 0.0, \"value\": 29134065956}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex\/Revestive, Takecab\/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate\/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid\/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin\/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse\/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd\/Fortis Advisors, Zedira\/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson\/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia\/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":100,"get_dividend_history_year2":198,"get_dividend_history_year3":192,"get_dividend_history_year4":184,"get_dividend_history_year5":180,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T03:10:00.340721\", \"ticker\": \"4502\", \"ticker_full\": \"4502.T\", \"company_name\": \"TAKEDA PHARMACEUTICAL CO LTD\", \"company_info\": {\"name_en\": \"TAKEDA PHARMACEUTICAL CO LTD\", \"long_name\": \"Takeda Pharmaceutical Company Limited\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.takeda.com\", \"employees\": 47029, \"country\": \"Japan\", \"city\": \"Chuo\", \"address\": \"1-1, Nihonbashi-Honcho 2-chome\", \"description\": \"Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex\/Revestive, Takecab\/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate\/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid\/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin\/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse\/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd\/Fortis Advisors, Zedira\/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson\/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia\/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 5714.6, \"deviation\": 0.86, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 5579.64, \"deviation\": 3.3, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 5287.73, \"deviation\": 9.01, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 5145.29, \"deviation\": 12.02, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 4505720000000.0, \"revenue_fmt\": \"\u00a54.5T\", \"gross_profit\": 2934132000000.0, \"gross_profit_fmt\": \"\u00a52.9T\", \"operating_income\": 464451000000.0, \"operating_income_fmt\": \"\u00a54645\u5104\", \"ebit\": 5768000000.0, \"ebit_fmt\": \"\u00a558\u5104\", \"net_income\": -152390000000.0, \"net_income_fmt\": \"-\u00a51524\u5104\", \"eps\": 119.64, \"operating_margin\": 10.31, \"total_assets\": 15511506000000.0, \"total_assets_fmt\": \"\u00a515.5T\", \"total_equity\": 7429441000000.0, \"total_equity_fmt\": \"\u00a57.4T\", \"total_debt\": 4881838000000.0, \"total_debt_fmt\": \"\u00a54.9T\", \"total_cash\": 595054000000.0, \"total_cash_fmt\": \"\u00a55951\u5104\", \"equity_ratio\": 47.9, \"de_ratio\": 0.66, \"current_ratio\": 1.09, \"operating_cf\": 1041431000000.0, \"operating_cf_fmt\": \"\u00a51.0T\", \"investing_cf\": -369141000000.0, \"investing_cf_fmt\": \"-\u00a53691\u5104\", \"financing_cf\": -496820000000.0, \"financing_cf_fmt\": \"-\u00a54968\u5104\", \"free_cf\": 626772000000.0, \"free_cf_fmt\": \"\u00a56268\u5104\", \"net_margin\": -3.38, \"roe\": -2.05, \"roa\": -0.98}, {\"year\": 2025, \"revenue\": 4581551000000.0, \"revenue_fmt\": \"\u00a54.6T\", \"gross_profit\": 3001334000000.0, \"gross_profit_fmt\": \"\u00a53.0T\", \"operating_income\": 466370000000.0, \"operating_income_fmt\": \"\u00a54664\u5104\", \"ebit\": 312395000000.0, \"ebit_fmt\": \"\u00a53124\u5104\", \"net_income\": 107928000000.0, \"net_income_fmt\": \"\u00a51079\u5104\", \"eps\": 67.23, \"operating_margin\": 10.18, \"total_assets\": 14248344000000.0, \"total_assets_fmt\": \"\u00a514.2T\", \"total_equity\": 6935084000000.0, \"total_equity_fmt\": \"\u00a56.9T\", \"total_debt\": 4515265000000.0, \"total_debt_fmt\": \"\u00a54.5T\", \"total_cash\": 385113000000.0, \"total_cash_fmt\": \"\u00a53851\u5104\", \"equity_ratio\": 48.67, \"de_ratio\": 0.65, \"current_ratio\": 1.01, \"operating_cf\": 1057182000000.0, \"operating_cf_fmt\": \"\u00a51.1T\", \"investing_cf\": -367060000000.0, \"investing_cf_fmt\": \"-\u00a53671\u5104\", \"financing_cf\": -751425000000.0, \"financing_cf_fmt\": \"-\u00a57514\u5104\", \"free_cf\": 677557000000.0, \"free_cf_fmt\": \"\u00a56776\u5104\", \"net_margin\": 2.36, \"roe\": 1.56, \"roa\": 0.76}, {\"year\": 2024, \"revenue\": 4263762000000.0, \"revenue_fmt\": \"\u00a54.3T\", \"gross_profit\": 2837084000000.0, \"gross_profit_fmt\": \"\u00a52.8T\", \"operating_income\": 309901000000.0, \"operating_income_fmt\": \"\u00a53099\u5104\", \"ebit\": 172326000000.0, \"ebit_fmt\": \"\u00a51723\u5104\", \"net_income\": 144067000000.0, \"net_income_fmt\": \"\u00a51441\u5104\", \"eps\": 91.16, \"operating_margin\": 7.27, \"total_assets\": 15108792000000.0, \"total_assets_fmt\": \"\u00a515.1T\", \"total_equity\": 7273264000000.0, \"total_equity_fmt\": \"\u00a57.3T\", \"total_debt\": 4843752000000.0, \"total_debt_fmt\": \"\u00a54.8T\", \"total_cash\": 457800000000.0, \"total_cash_fmt\": \"\u00a54578\u5104\", \"equity_ratio\": 48.14, \"de_ratio\": 0.67, \"current_ratio\": 1.11, \"operating_cf\": 716344000000.0, \"operating_cf_fmt\": \"\u00a57163\u5104\", \"investing_cf\": -463862000000.0, \"investing_cf_fmt\": \"-\u00a54639\u5104\", \"financing_cf\": -354416000000.0, \"financing_cf_fmt\": \"-\u00a53544\u5104\", \"free_cf\": 235614000000.0, \"free_cf_fmt\": \"\u00a52356\u5104\", \"net_margin\": 3.38, \"roe\": 1.98, \"roa\": 0.95}, {\"year\": 2023, \"revenue\": 4027478000000.0, \"revenue_fmt\": \"\u00a54.0T\", \"gross_profit\": 2783406000000.0, \"gross_profit_fmt\": \"\u00a52.8T\", \"operating_income\": 587812000000.0, \"operating_income_fmt\": \"\u00a55878\u5104\", \"ebit\": 492063000000.0, \"ebit_fmt\": \"\u00a54921\u5104\", \"net_income\": 317017000000.0, \"net_income_fmt\": \"\u00a53170\u5104\", \"eps\": 201.94, \"operating_margin\": 14.6, \"total_assets\": 13957750000000.0, \"total_assets_fmt\": \"\u00a514.0T\", \"total_equity\": 6354122000000.0, \"total_equity_fmt\": \"\u00a56.4T\", \"total_debt\": 4382341000000.0, \"total_debt_fmt\": \"\u00a54.4T\", \"total_cash\": 533530000000.0, \"total_cash_fmt\": \"\u00a55335\u5104\", \"equity_ratio\": 45.52, \"de_ratio\": 0.69, \"current_ratio\": 0.97, \"operating_cf\": 977156000000.0, \"operating_cf_fmt\": \"\u00a59772\u5104\", \"investing_cf\": -607102000000.0, \"investing_cf_fmt\": \"-\u00a56071\u5104\", \"financing_cf\": -709148000000.0, \"financing_cf_fmt\": \"-\u00a57091\u5104\", \"free_cf\": 343467000000.0, \"free_cf_fmt\": \"\u00a53435\u5104\", \"net_margin\": 7.87, \"roe\": 4.99, \"roa\": 2.27}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 180.0}, {\"year\": 2023, \"amount\": 184.0}, {\"year\": 2024, \"amount\": 192.0}, {\"year\": 2025, \"amount\": 198.0}, {\"year\": 2026, \"amount\": 100.0}], \"latest\": 100.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-6852","company","type-company","status-publish","hentry"],"yoast_head":"\n